First Trust Advisors LP decreased its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 18.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 8,280 shares of the medical instruments supplier’s stock after selling 1,908 shares during the period. First Trust Advisors LP’s holdings in ICU Medical were worth $1,428,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Parametrica Management Ltd acquired a new position in ICU Medical during the second quarter worth approximately $213,000. Ameritas Investment Partners Inc. acquired a new position in ICU Medical during the first quarter worth approximately $194,000. Quantitative Systematic Strategies LLC acquired a new position in ICU Medical during the second quarter worth approximately $233,000. Reliance Trust Co. of Delaware acquired a new position in ICU Medical during the second quarter worth approximately $271,000. Finally, Janney Montgomery Scott LLC increased its position in ICU Medical by 0.4% during the first quarter. Janney Montgomery Scott LLC now owns 1,607 shares of the medical instruments supplier’s stock worth $245,000 after buying an additional 7 shares during the period. 78.13% of the stock is currently owned by institutional investors.
In other news, Chairman Vivek Jain sold 100,000 shares of the stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $170.80, for a total transaction of $17,080,000.00. Following the sale, the chairman now directly owns 110,925 shares in the company, valued at approximately $18,945,990. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert S. Swinney sold 4,477 shares of the stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $175.00, for a total value of $783,475.00. Following the sale, the director now owns 23,293 shares in the company, valued at $4,076,275. The disclosure for this sale can be found here. Insiders have sold a total of 213,012 shares of company stock worth $36,438,659 over the last quarter. Insiders own 15.90% of the company’s stock.
ICU Medical, Inc. (NASDAQ:ICUI) opened at 180.05 on Friday. The firm has a market cap of $3.57 billion, a price-to-earnings ratio of 72.11 and a beta of 0.36. The stock has a 50 day moving average price of $172.54 and a 200-day moving average price of $163.75. ICU Medical, Inc. has a 12-month low of $121.76 and a 12-month high of $182.45.
ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Wednesday, August 9th. The medical instruments supplier reported $0.52 earnings per share for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.06). The company had revenue of $331.51 million for the quarter, compared to analyst estimates of $318.30 million. ICU Medical had a return on equity of 7.56% and a net margin of 6.10%. The firm’s revenue for the quarter was up 242.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.15 earnings per share. Equities analysts forecast that ICU Medical, Inc. will post $4.11 earnings per share for the current year.
ICUI has been the topic of several research analyst reports. BidaskClub raised ICU Medical from a “hold” rating to a “buy” rating in a research report on Saturday, June 17th. Sidoti lowered ICU Medical from a “buy” rating to a “neutral” rating in a report on Tuesday, June 20th. Zacks Investment Research raised ICU Medical from a “hold” rating to a “strong-buy” rating and set a $195.00 target price on the stock in a report on Wednesday, July 12th. Finally, Gabelli reissued a “buy” rating on shares of ICU Medical in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. ICU Medical currently has an average rating of “Hold” and an average target price of $193.00.
ICU Medical Profile
ICU Medical, Inc is engaged in the development, manufacture and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company’s product line includes needlefree connection devices, custom infusion sets, closed system transfer devices (CSTD) for the handling of hazardous drugs, advanced sensor catheters, needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems.
Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Inc. (NASDAQ:ICUI).
Receive News & Ratings for ICU Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.